Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception: a Cochrane systematic review.

Katie Hansen Megan A CohenShaalini RamanadhanRobin PaynterAlison EdelmanJillian T Henderson

Published in: BMJ sexual & reproductive health (2023)

Not enough evidence exists to draw conclusions regarding risk of thromboembolism in patients with COVID-19 using hormonal contraception. Evidence suggests there may be little to no or slightly decreased odds of hospitalisation, and little to no effect on odds of mortality for hormonal contraception users versus non-users with COVID-19.

Keyphrases

systematic review
polycystic ovary syndrome
coronavirus disease
sars cov
meta analyses
cardiovascular events
risk factors
insulin resistance
cardiovascular disease
metabolic syndrome
coronary artery disease